Lannett Co Inc Revenue 2006-2019 | LCI

Lannett Co Inc revenue from 2006 to 2019. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Lannett Co Inc Annual Revenue
(Millions of US $)
2018 $685
2017 $633
2016 $542
2015 $407
2014 $274
2013 $151
2012 $123
2011 $107
2010 $125
2009 $119
2008 $72
2007 $83
2006 $64
2005 $45
Lannett Co Inc Quarterly Revenue
(Millions of US $)
Q3 2019 $173
Q2 2018 $194
Q1 2018 $155
Q4 2018 $171
Q3 2018 $174
Q2 2017 $184
Q1 2017 $155
Q4 2017 $139
Q3 2017 $162
Q2 2016 $171
Q1 2016 $162
Q4 2016 $169
Q3 2016 $140
Q2 2015 $127
Q1 2015 $106
Q4 2015 $99
Q3 2015 $99
Q2 2014 $115
Q1 2014 $93
Q4 2014 $81
Q3 2014 $80
Q2 2013 $67
Q1 2013 $46
Q4 2013 $40
Q3 2013 $39
Q2 2012 $37
Q1 2012 $35
Q4 2012 $36
Q3 2012 $31
Q2 2011 $28
Q1 2011 $29
Q4 2011 $26
Q3 2011 $26
Q2 2010 $30
Q1 2010 $25
Q4 2010 $34
Q3 2010 $31
Q2 2009 $29
Q1 2009 $31
Q4 2009 $35
Q3 2009 $29
Q2 2008 $29
Q1 2008 $26
Q4 2008 $21
Q3 2008 $17
Q2 2007 $18
Q1 2007 $18
Q4 2007 $17
Q3 2007 $20
Q2 2006 $23
Q1 2006 $22
Q4 2006 $19
Q3 2006 $16
Q2 2005 $15
Q1 2005 $14
Q4 2005 $9
Q3 2005 $8
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.221B $0.685B
Lannett Company manufactures and distributes high quality affordable generic medications that are the therapeutic equivalent of the brand-name pharmaceuticals. Their portfolio consists of numerous products across a wide range of therapeutic areas. Lannett believes that their ability to select viable products for development, efficiently develop such products, including obtaining any applicable regulatory approvals, vertically integrate themselves into certain specialty markets and achieve economies in production are all critical for their success in the generic pharmaceutical industry in which they operate. Lannett Company, Inc., continues to dedicate significant capital toward developing new products as they believe their success is linked to their ability to continually introduce new generic products into the marketplace.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $55.017B 35.15
Astellas Pharma (ALPMY) Japan $28.057B 13.76
Takeda Pharmaceutical (TAK) Japan $27.185B 7.98
UCB SA (UCBJF) Belgium $15.866B 0.00
Eisai (ESALY) Japan $15.800B 27.17
Grifols, S.A (GRFS) Spain $15.229B 19.26
Merck (MKGAF) Germany $13.816B 18.85
IPSEN SA ADR (IPSEY) France $10.783B 0.00
Ionis Pharmaceuticals (IONS) United States $9.884B 21.61
Sage Therapeutics (SAGE) United States $9.504B 0.00
Ono Pharmaceutical (OPHLF) Japan $9.254B 19.78
Neurocrine Biosciences (NBIX) United States $8.080B 0.00
Catalent (CTLT) United States $7.911B 31.75
Jazz Pharmaceuticals (JAZZ) Ireland $7.829B 10.73
Recordati Industria Chimica E Farmaceutica S.P.A (RCDTF) Italy $7.257B 19.83
STADA ARZNEIMI (STDAF) Germany $5.634B 0.00
Nektar Therapeutics (NKTR) United States $5.590B 9.11
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $5.420B 0.00
Orion OYJ (ORINY) Finland $5.275B 27.16
Hypermarcas (HYPMY) Brazil $4.938B 17.36
Evotec AG (EVTCY) Germany $4.267B 45.80
Tilray (TLRY) Canada $4.221B 0.00
FibroGen (FGEN) United States $4.109B 0.00
United Therapeutics (UTHR) United States $3.341B 0.00
Taro Pharmaceutical Industries (TARO) Israel $3.244B 11.64
Arrowhead Pharmaceuticals (ARWR) United States $2.809B 423.29
PTC Therapeutics (PTCT) United States $2.570B 0.00
Xencor (XNCR) United States $2.569B 70.14
Zogenix (ZGNX) United States $2.033B 0.00
Portola Pharmaceuticals (PTLA) United States $1.831B 0.00
Pacira Pharmaceuticals (PCRX) United States $1.671B 80.92
Ironwood Pharmaceuticals (IRWD) United States $1.649B 0.00
Enanta Pharmaceuticals (ENTA) United States $1.641B 22.43
CLINIGEN GP (CLIGF) United Kingdom $1.577B 0.00
Heron Therapeutics (HRTX) United States $1.521B 0.00
USANA Health Sciences (USNA) United States $1.461B 12.70
Corcept Therapeutics (CORT) United States $1.254B 17.90
ArQule (ARQL) United States $1.162B 0.00
Aerie Pharmaceuticals (AERI) United States $1.085B 0.00
Radius Health (RDUS) United States $1.032B 0.00
Theravance Biopharma (TBPH) Cayman Islands $1.031B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $1.013B 3.65
Spectrum Pharmaceuticals (SPPI) United States $0.907B 0.00
Endo (ENDP) Ireland $0.755B 1.21
Concordia (CXRXF) Canada $0.719B 0.00
Aptorum Group (APM) China $0.649B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $0.581B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.579B 0.00
Organogenesis Holdings (ORGO) United States $0.566B 0.00
TherapeuticsMD (TXMD) United States $0.548B 0.00
GlycoMimetics (GLYC) United States $0.513B 0.00
Karyopharm Therapeutics (KPTI) United States $0.509B 0.00
Translate Bio (TBIO) United States $0.489B 0.00
ChemoCentryx (CCXI) United States $0.481B 0.00
Siga Technologies (SIGA) United States $0.460B 1.08
Dova Pharmaceuticals (DOVA) United States $0.453B 0.00
Akebia Therapeutics (AKBA) United States $0.453B 0.00
Dermira (DERM) United States $0.452B 0.00
BioSpecifics Technologies Corp (BSTC) United States $0.445B 22.43
Catalyst Pharmaceuticals (CPRX) United States $0.426B 0.00
CV Sciences (CVSI) United States $0.421B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.416B 0.00
Flexion Therapeutics (FLXN) United States $0.415B 0.00
CannTrust Holdings (CTST) Canada $0.414B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.400B 0.00
Indivior (INVVY) United States $0.398B 1.44
MARKER THERAPEUTICS, INC (MRKR) United States $0.396B 0.00
BioCryst Pharmaceuticals (BCRX) United States $0.384B 0.00
Innate Pharma SA (IPHYF) France $0.369B 0.00
Harpoon Therapeutics (HARP) United States $0.358B 0.00
Collegium Pharmaceutical (COLL) United States $0.352B 0.00
ImmunoGen (IMGN) United States $0.345B 0.00
Xeris Pharmaceuticals (XERS) United States $0.322B 0.00
KalVista Pharmaceuticals (KALV) United States $0.304B 0.00
Rafael Holdings (RFL) United States $0.297B 0.00
Molecular Templates (MTEM) United States $0.279B 0.00
OptiNose (OPTN) United States $0.263B 0.00
Concert Pharmaceuticals (CNCE) United States $0.260B 0.00
Aratana Therapeutics (PETX) United States $0.241B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.238B 0.00
AcelRx Pharmaceuticals (ACRX) United States $0.222B 0.00
Recro Pharma (REPH) United States $0.221B 0.00
Ocular Therapeutix (OCUL) United States $0.208B 0.00
ASSERTIO THERAPEUTICS, INC (ASRT) United States $0.189B 0.00
Nature's Sunshine Products (NATR) United States $0.175B 56.88
Redhill Biopharma (RDHL) Israel $0.172B 0.00
Calithera Biosciences (CALA) United States $0.168B 0.00
Taiwan Liposome (TLC) Taiwan $0.161B 0.00
Ardelyx (ARDX) United States $0.161B 0.00
IMV INC (IMV) Canada $0.157B 0.00
Oasmia Pharmaceutical AB (OASM) Sweden $0.150B 0.00
Jounce Therapeutics (JNCE) United States $0.139B 0.00
MEI Pharma (MEIP) United States $0.138B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.135B 0.00
Majesco Entertainment (PTE) United States $0.134B 0.00
Foamix Pharmaceuticals (FOMX) Israel $0.127B 0.00
Generex Biotechnology (GNBT) United States $0.110B 0.00
DURECT (DRRX) United States $0.109B 0.00
Matinas Biopharma Holdings (MTNB) United States $0.107B 0.00
AgeX Therapeutics (AGE) United States $0.105B 0.00
Aquestive Therapeutics (AQST) United States $0.103B 0.00
RENEURON GP (RNUGF) United Kingdom $0.098B 0.00
Infinity Pharmaceuticals (INFI) United States $0.094B 0.00
Iterum Therapeutics (ITRM) Ireland $0.093B 0.00
MediWound (MDWD) Israel $0.093B 0.00
Capnia (SLNO) United States $0.091B 0.00
Champions Oncology (CSBR) United States $0.090B 0.00
Genocea Biosciences (GNCA) United States $0.090B 0.00
Mast Therapeutics (SVRA) United States $0.090B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.089B 63.33
Aclaris Therapeutics (ACRS) United States $0.087B 0.00
Nivalis Therapeutics (ALPN) United States $0.085B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.084B 0.00
Entasis Therapeutics Holdings (ETTX) United States $0.082B 0.00
Natural Alternatives (NAII) United States $0.081B 8.08
Bellicum Pharmaceuticals (BLCM) United States $0.080B 0.00
China SXT Pharmaceuticals (SXTC) China $0.078B 0.00
Cardiome Pharma (CORV) Canada $0.077B 0.00
Otonomy (OTIC) United States $0.077B 0.00
Novan (NOVN) United States $0.072B 0.00
Neos Therapeutics (NEOS) United States $0.070B 0.00
Pharmaxis (PXSLY) Australia $0.067B 0.00
SCYNEXIS (SCYX) United States $0.065B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.060B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.056B 0.00
Medicure (MCUJF) Canada $0.053B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.052B 0.00
India Globalization Capital (IGC) United States $0.052B 0.00